DK1404357T3 - Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer - Google Patents

Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer

Info

Publication number
DK1404357T3
DK1404357T3 DK02749000.2T DK02749000T DK1404357T3 DK 1404357 T3 DK1404357 T3 DK 1404357T3 DK 02749000 T DK02749000 T DK 02749000T DK 1404357 T3 DK1404357 T3 DK 1404357T3
Authority
DK
Denmark
Prior art keywords
gonadotropin
gel
releasing hormone
hormone antagonist
forming concentrations
Prior art date
Application number
DK02749000.2T
Other languages
English (en)
Inventor
Pierre Broqua
Martin Lueck
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK1404357T3 publication Critical patent/DK1404357T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK02749000.2T 2001-07-12 2002-07-08 Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer DK1404357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition
PCT/GB2002/003116 WO2003006049A1 (en) 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonists in gel-forming concentrations

Publications (1)

Publication Number Publication Date
DK1404357T3 true DK1404357T3 (da) 2010-05-03

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02749000.2T DK1404357T3 (da) 2001-07-12 2002-07-08 Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer

Country Status (13)

Country Link
US (4) US20050245455A1 (da)
EP (1) EP1404357B1 (da)
JP (1) JP4845166B2 (da)
AR (1) AR036337A1 (da)
AT (1) ATE452648T1 (da)
DE (1) DE60234831D1 (da)
DK (1) DK1404357T3 (da)
ES (1) ES2338217T3 (da)
GB (1) GB0117057D0 (da)
MY (1) MY139203A (da)
PT (1) PT1404357E (da)
UY (1) UY27378A1 (da)
WO (1) WO2003006049A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
RS52966B (sr) 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
PT1684782E (pt) 2003-10-03 2015-12-21 Thorn Bioscience Llc Processo para a sincronização da ovulação para reprodução regulada sem detecção do cio
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
CA2671925A1 (en) * 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
SG11201407679PA (en) 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix
ITMI20121638A1 (it) 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
DK2925339T3 (da) 2012-11-28 2020-07-20 United Ah Ii Llc Fremgangsmåde til synkronisering af inseminationstidspunkt hos gylte
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
JP6990717B2 (ja) * 2017-01-30 2022-02-03 アンテヴ リミテッド 少なくとも１種のｇｎｒｈアンタゴニストを含む組成物
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US8105292B2 (en) * 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
PT2632934T (pt) * 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2731607B1 (en) * 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
US20110053846A1 (en) 2011-03-03
EP1404357A1 (en) 2004-04-07
EP1404357B1 (en) 2009-12-23
PT1404357E (pt) 2010-03-16
JP4845166B2 (ja) 2011-12-28
US20090018085A1 (en) 2009-01-15
ATE452648T1 (de) 2010-01-15
JP2005511491A (ja) 2005-04-28
DE60234831D1 (de) 2010-02-04
ES2338217T3 (es) 2010-05-05
WO2003006049A1 (en) 2003-01-23
US20040038903A1 (en) 2004-02-26
AR036337A1 (es) 2004-09-01
GB0117057D0 (en) 2001-09-05
UY27378A1 (es) 2003-02-28
MY139203A (en) 2009-08-28
US20050245455A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
DK1404357T3 (da) Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer
NO20003196L (no) Umiddelbart opplösende doseringsformulering
NO20032101D0 (no) Apoliprotein analoger
ATE285675T1 (de) Zaun
NO20034188D0 (no) Skinnestent
NO20033384L (no) Farmasoytisk formulering
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
NO20033785D0 (no) Farmasöytisk formulering
EE200200490A (et) Kinoliini derivaadid alfa-2 antagonistidena
DE60226425D1 (de) Lösliches rage-protein
NO20035627D0 (no) Farmasöytisk formulering
DE60202258D1 (de) Feuermelder
DE50207930D1 (de) Sicherungsbauelement
DE60222693D1 (de) Nk1-antagonisten
DK1372688T3 (da) Somatostatin-antagonister
NO20042449L (no) Injeksjonslosning omfattende en LHRH-antagonist
DE60104126D1 (de) Fungizide formulierung
IS8360A (is) Mótlyf styrkthjöppunarhormóns melaníns
NO20032963D0 (no) Peptidforbindelser
FI20002757L (fi) Päätelaitteen paikannus
PL362793A1 (pl) Antagoniści reseptorów histaminowych
DE50203715D1 (de) Elektrodenleitung
DE10290319D2 (de) Anschlussklemme
ITBO20010052A0 (it) Dispositivo di recinzione con occultamento
ATE354561T1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen